A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.
Hilary Glen(Beatson West of Scotland Cancer Centre), Sumanta K. Pal(City of Hope), Corina E. Dutcus(Eisai (United States)), Javier Puente(Hospital Clínico San Carlos), Daniel E. Stepan(Eisai (United States)), Di Li(Air Force General Hospital PLA), Daniel Yick Chin Heng(University of Calgary), Sun Young Rha(Yonsei University)
Cited by 4
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766